• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.

Peer Exchange

AJMC® Peer Exchange® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's cancer care professionals.

Emerging Treatment Options in Relapsed Refractory Multiple Myeloma

EP. 1: R/R Multiple Myeloma Rationale for Decreased Response
EP. 1: R/R Multiple Myeloma Rationale for Decreased Response
EP. 2: Importance of MRD Negativity in Changing Relapse Patterns
EP. 2: Importance of MRD Negativity in Changing Relapse Patterns
EP. 3: Treating Biochemical Relapses in Multiple Myeloma
EP. 3: Treating Biochemical Relapses in Multiple Myeloma
EP. 4: Upfront Daratumumab Impact on Relapse Treatment
EP. 4: Upfront Daratumumab Impact on Relapse Treatment
EP. 5: CANDOR Trial Overview and Regimen Complications
EP. 5: CANDOR Trial Overview and Regimen Complications
EP. 6: Clinical Significance of DKd Dosing Flexibility
EP. 6: Clinical Significance of DKd Dosing Flexibility
EP. 7: Therapy Selection for Newly Diagnosed Multiple Myeloma
EP. 7: Therapy Selection for Newly Diagnosed Multiple Myeloma

Acute and Preventive Therapy for Migraine

EP. 1: Acute and Preventive Treatment: Differences and QOL Impact
EP. 1: Acute and Preventive Treatment: Differences and QOL Impact
EP. 2: Acute Migraine Treatment: Prevalence and Classes of Agents
EP. 2: Acute Migraine Treatment: Prevalence and Classes of Agents
EP. 3: Acute Migraine Therapy Unmet Needs
EP. 3: Acute Migraine Therapy Unmet Needs
EP. 4: Drivers of Health Care Utilization for Uncontrolled Migraine
EP. 4: Drivers of Health Care Utilization for Uncontrolled Migraine
EP. 5: Advancements in Migraine Diagnosis and Treatment
EP. 5: Advancements in Migraine Diagnosis and Treatment
EP. 6: Determining and Measuring Individualized Treatment Goals
EP. 6: Determining and Measuring Individualized Treatment Goals
EP. 7: Transitioning from Acute to Preventive Care
EP. 7: Transitioning from Acute to Preventive Care
EP. 8: Historical Perspective on Preventive Care
EP. 8: Historical Perspective on Preventive Care
EP. 9: New CGRP Monoclonal Antibodies for Preventive Care
EP. 9: New CGRP Monoclonal Antibodies for Preventive Care
EP. 10: CGRP Monoclonal Antibodies: AEs and Efficacy
EP. 10: CGRP Monoclonal Antibodies: AEs and Efficacy
EP. 11: Patient-Reported Outcomes Data on Adverse Events
EP. 11: Patient-Reported Outcomes Data on Adverse Events
EP. 12: Migraine Therapy Selection and Duration
EP. 12: Migraine Therapy Selection and Duration
EP. 13: Measuring Response in Goal-Based Therapy
EP. 13: Measuring Response in Goal-Based Therapy
EP. 14: Combining Acute and Preventive Therapy
EP. 14: Combining Acute and Preventive Therapy
EP. 15: Managing Migraine Patients During the Pandemic
EP. 15: Managing Migraine Patients During the Pandemic

Implications of Expanding Use of CAR T-Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

EP. 1: Overview of CAR T-cell Therapy in R/R NHL
EP. 1: Overview of CAR T-cell Therapy in R/R NHL
EP. 2: Transplant-Eligibility and CAR T Considerations in R/R NHL
EP. 2: Transplant-Eligibility and CAR T Considerations in R/R NHL
EP. 3: ZUMA-1 Trial Using CAR T in R/R NHL
EP. 3: ZUMA-1 Trial Using CAR T in R/R NHL
EP. 4: Optimizing CAR T in R/R NHL
EP. 4: Optimizing CAR T in R/R NHL
EP. 5: Emerging Therapies and Future of CAR T-Cell Therapy
EP. 5: Emerging Therapies and Future of CAR T-Cell Therapy
EP. 6: Patient Selection of CAR T-Cell Therapy in R/R NHL
EP. 6: Patient Selection of CAR T-Cell Therapy in R/R NHL
EP. 7: Barriers to CAR T Therapy for R/R NHL
EP. 7: Barriers to CAR T Therapy for R/R NHL
EP. 8: Value of Outpatient CAR T Administration in R/R NHL
EP. 8: Value of Outpatient CAR T Administration in R/R NHL
EP. 9: Requirements for CAR T in a Community Setting
EP. 9: Requirements for CAR T in a Community Setting
EP. 10: Outpatient CAR T in R/R NHL: Policies and Procedures
EP. 10: Outpatient CAR T in R/R NHL: Policies and Procedures
EP. 11: Role of CAR T Administration in the Community
EP. 11: Role of CAR T Administration in the Community
EP. 12: Educating Providers for Outpatient CAR T Administration
EP. 12: Educating Providers for Outpatient CAR T Administration
EP. 13: Importance of Monitoring Patient AEs With Outpatient CAR T
EP. 13: Importance of Monitoring Patient AEs With Outpatient CAR T
EP. 14: Management of Outpatient CAR T Adverse Events
EP. 14: Management of Outpatient CAR T Adverse Events
EP. 15: Evolving Treatment Paradigm of R/R NHL and Outpatient CAR T
EP. 15: Evolving Treatment Paradigm of R/R NHL and Outpatient CAR T
EP. 16: Future of Outpatient CAR T Administration
EP. 16: Future of Outpatient CAR T Administration

Supporting Cross-Benefit Management of Infused Drugs

EP. 1: Choosing Drug-related Routes of Administration
EP. 1: Choosing Drug-related Routes of Administration
EP. 2: Routes of Administration: Adherence and Persistence
EP. 2: Routes of Administration: Adherence and Persistence
EP. 3: Alignment of Incentives: Optimizing Routes of Administration
EP. 3: Alignment of Incentives: Optimizing Routes of Administration
EP. 4: Cost Considerations for Self- vs HCP-administered Agents
EP. 4: Cost Considerations for Self- vs HCP-administered Agents
EP. 5: Preferred Site of Care and Coverage for Infusions
EP. 5: Preferred Site of Care and Coverage for Infusions
EP. 6: Utilization Management Through Medical and Pharmacy Benefit
EP. 6: Utilization Management Through Medical and Pharmacy Benefit
EP. 7: Cost Dispersion of Infused Drugs
EP. 7: Cost Dispersion of Infused Drugs
EP. 8: Self-injectables: Emerging Agents for the Management of MS
EP. 8: Self-injectables: Emerging Agents for the Management of MS
EP. 9: Evolving Management of Drug Spending Monitoring
EP. 9: Evolving Management of Drug Spending Monitoring
EP. 10: Transparency Among Medical and Pharmacy Benefits
EP. 10: Transparency Among Medical and Pharmacy Benefits
EP. 11: Management of Drug Spending and Impact of COVID-19
EP. 11: Management of Drug Spending and Impact of COVID-19
EP. 12: Future of Medical and Pharmacy Benefit Integration
EP. 12: Future of Medical and Pharmacy Benefit Integration

Considering Cost Effectiveness in Cardiovascular Risk Reduction

EP. 1: Economic Burden of Cardiovascular Disease
EP. 1: Economic Burden of Cardiovascular Disease
EP. 2: Risk Assessment for Cardiovascular Disease
EP. 2: Risk Assessment for Cardiovascular Disease
EP. 3: LDL Cholesterol Lowering and CV Risk
EP. 3: LDL Cholesterol Lowering and CV Risk
EP. 4: Cardiovascular Risk Management
EP. 4: Cardiovascular Risk Management
EP. 5: Dyslipidemia: Strategies Used to Reduce CV Risk
EP. 5: Dyslipidemia: Strategies Used to Reduce CV Risk
EP. 6: Statin Therapy for LDL Reduction and CV Risk
EP. 6: Statin Therapy for LDL Reduction and CV Risk
EP. 7: Statin Therapy: Risk for Future CV Events
EP. 7: Statin Therapy: Risk for Future CV Events
EP. 8: PCSK9 Inhibitors and CV Risk
EP. 8: PCSK9 Inhibitors and CV Risk
EP. 9: Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
EP. 9: Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
EP. 10: Targeting Triglycerides to Reduce CV Risk
EP. 10: Targeting Triglycerides to Reduce CV Risk
EP. 11: The REDUCE-IT Study and CV Risk
EP. 11: The REDUCE-IT Study and CV Risk
EP. 12: Interim Analysis of EVAPORATE
EP. 12: Interim Analysis of EVAPORATE
EP. 13: Coronary Plaque Regression and CV Risk
EP. 13: Coronary Plaque Regression and CV Risk
EP. 14: Implications for Treating Patients With Icosapent Ethyl
EP. 14: Implications for Treating Patients With Icosapent Ethyl
EP. 15: Cost-Effectiveness and Cardiovascular Risk
EP. 15: Cost-Effectiveness and Cardiovascular Risk
EP. 16: Cardiovascular Disease Treatment Decisions and Cost
EP. 16: Cardiovascular Disease Treatment Decisions and Cost
EP. 17: CV Risk Reduction and Coverage of Therapies
EP. 17: CV Risk Reduction and Coverage of Therapies
EP. 18: Cost-Effectiveness Data and Pricing of Icosapent Ethyl
EP. 18: Cost-Effectiveness Data and Pricing of Icosapent Ethyl
EP. 19: CVD: Cost-Effectiveness Data and Treatment Selection
EP. 19: CVD: Cost-Effectiveness Data and Treatment Selection
EP. 20: Clinical Pathways for Cardiovascular Disease Management
EP. 20: Clinical Pathways for Cardiovascular Disease Management
EP. 21: Better Strategies to Reduce Cardiovascular Events
EP. 21: Better Strategies to Reduce Cardiovascular Events

Quantifying the Potential Impact of SGLT-2 Inhibitors in Heart Failure

EP. 1: Pathophysiology of Different Types of Heart Failure
EP. 1: Pathophysiology of Different Types of Heart Failure
EP. 2: Progressive Nature and Associated Risks of Diabetes on HF
EP. 2: Progressive Nature and Associated Risks of Diabetes on HF
EP. 3: Cost and Utilization Profile for a Patient With HF
EP. 3: Cost and Utilization Profile for a Patient With HF
EP. 4: Economic Burden of Heart Failure and Goals of Treatment
EP. 4: Economic Burden of Heart Failure and Goals of Treatment
EP. 5: Standard of Care in Patients With Heart Failure
EP. 5: Standard of Care in Patients With Heart Failure
EP. 6: Reducing Readmissions Due to Heart Failure
EP. 6: Reducing Readmissions Due to Heart Failure
EP. 7: CV Outcomes Studies With Medications Indicated for Diabetes
EP. 7: CV Outcomes Studies With Medications Indicated for Diabetes
EP. 8: Recent Studies of SGLT-2s in Patients with HFrEF
EP. 8: Recent Studies of SGLT-2s in Patients with HFrEF
EP. 9: Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF
EP. 9: Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF
EP. 10: SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF
EP. 10: SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF
EP. 11: SGLT2 Inhibitors as Standard of Care Throughout Cardiology
EP. 11: SGLT2 Inhibitors as Standard of Care Throughout Cardiology
EP. 12: Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF
EP. 12: Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF
EP. 13: Quantifying Potential Impact of SGLT2 Inhibitors for HF
EP. 13: Quantifying Potential Impact of SGLT2 Inhibitors for HF
EP. 14: Systemic Change to Support Care of Patients With HF
EP. 14: Systemic Change to Support Care of Patients With HF
EP. 15: Treatment of Patients With Heart Failure
EP. 15: Treatment of Patients With Heart Failure
EP. 16: Interest Regarding Diabetes and CVD Risk
EP. 16: Interest Regarding Diabetes and CVD Risk
EP. 17: Takeaways of DAPA-HF: SGLT2s for CVD
EP. 17: Takeaways of DAPA-HF: SGLT2s for CVD
EP. 18: Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits
EP. 18: Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits
EP. 19: Cost-Effectiveness of SGLT2s for CVD
EP. 19: Cost-Effectiveness of SGLT2s for CVD